Right Ventricular Metrics as End Points in Clinical Trials: A Review

JAMA Cardiol. 2026 Jun 24. doi: 10.1001/jamacardio.2026.2053. Online ahead of print.ABSTRACTIMPORTANCE: Clinical trials in cardiovascular medicine aim to deliver high-quality evidence with greater efficiency, including smaller sample sizes and shorter timelines. The selection of sensitive and reliab

E Elena Surkova

Model-guided medicine for early diagnosis of transthyretin-associated cardiac amyloidosis using multimodal data integration and standardized interoperable models (the CRONOS-ATTR study)

Int J Comput Assist Radiol Surg. 2026 Jun 24. doi: 10.1007/s11548-026-03640-0. Online ahead of print.ABSTRACTBACKGROUND: Early diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is essential for timely intervention but remains challenging due to its subtle and nonspecific clinical presentation

R Raúl Ramos-Polo

Clinical Pharmacology of Plozasiran

Am J Cardiovasc Drugs. 2026 Jun 24. doi: 10.1007/s40256-026-00808-6. Online ahead of print.ABSTRACTHypertriglyceridemia can increase the risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Patients with familial chylomicronemia syndrome are at an even higher risk of develo

J Jessica Huston

Noise and the heart

Herz. 2026 Jun 24. doi: 10.1007/s00059-026-05383-9. Online ahead of print.ABSTRACTTraffic-related environmental noise represents a widespread and relevant environmental factor in Europe that is associated with a substantial burden of disease. Current estimates indicate that a significant proportion

O Omar Hahad

The Role of Ammonia in Particle Toxicity

No abstractJ Am Coll Cardiol. 2026 Jun 9:S0735-1097(26)06487-9. doi: 10.1016/j.jacc.2026.05.003. Online ahead of print.NO ABSTRACTPMID:42340292 | DOI:10.1016/j.jacc.2026.05.003

G George D Thurston

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis

Am J Ther. 2026 Jun 25. doi: 10.1097/MJT.0000000000002156. Online ahead of print.ABSTRACTBACKGROUND: Cardiovascular disease remains the leading cause of global mortality (19.8 million deaths in 2022; 32% of all deaths worldwide). Drug repurposing-extending approved agents beyond their original indic

O Oana-Monica Leah

Who Falls After a Stroke? Evidence From a Prospective Stroke Cohort

Eur J Neurol. 2026 Jun;33(6):e70678. doi: 10.1111/ene.70678.ABSTRACTBACKGROUND: Falls affect over 30% of stroke survivors within the first year, yet lesion-related mobility and gait impairments underlying fall risk remain poorly understood. This study aimed to identify lesion-derived functional netw

A Anna Kufner